Inovio präsentiert DNA-Medikamente auf wissenschaftlichen Fachkonferenzen

• Inovio nimmt am 8. November 2026 am dritten internationalen Soft-Bones-Treffen zu Hypophosphatasie in New York teil; Thema sind DNA-basierte Proteinersatztherapien.
• Am 12. November 2026 folgt die Präsentation von INO-D001 gegen Hämophilie A beim NTGT-Workshop der World Federation of Hemophilia in Montreal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611021601PR_NEWS_USPR_____PH87086) on November 02, 2026, and is solely responsible for the information contained therein.